The Role of Novel (Tobacco) Products on Tobacco Control in Italy.

Italy e-cigarette harm reduction heat-not-burn tobacco products heated tobacco products smoking prevalence

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
16 02 2021
Historique:
received: 14 01 2021
revised: 10 02 2021
accepted: 11 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 27 4 2021
Statut: epublish

Résumé

In Italy, electronic cigarettes have spread since 2010 and heated tobacco products (HTP) since 2016. We investigated their public health consequences on conventional cigarette smoking, taking advantage of a series of cross-sectional studies annually conducted between 2001 and 2019 in Italy. Every year, the sample, including around 3000 individuals, was representative of the general Italian population aged ≥15 years. In Italy, smoking prevalence steadily declined from 29.1% in 2001 to 20.6% in 2013, then increased to 22.0% in 2019. In 2017-2019, current electronic cigarette users were 2.1% and in 2019 current HTP users were 1.1%. Among 498 ever electronic cigarette users, 23.2% started or re-started smoking and 15.7% quit smoking after electronic cigarette use; of 49 ever HTP users, 19.1% started or re-started smoking combusted cigarettes and 14.6% quit smoking after HTP use. The availability of novel products in Italy resulted in a halt of the decreasing trend in smoking prevalence. For the first time, we observed an increase of Italians inhaling nicotine, concurrently with the spread of novel (tobacco) products. More importantly, the use of novel products appears to increase-rather than decrease-the likelihood of smoking conventional cigarettes. Considering this evidence, we see no argument to justify the huge fiscal and regulatory benefits these products continue to have, at least in Italy.

Identifiants

pubmed: 33669394
pii: ijerph18041895
doi: 10.3390/ijerph18041895
pmc: PMC7920305
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Environ Res Public Health. 2020 Nov 19;17(22):
pubmed: 33227929
Am J Health Behav. 2015 May;39(3):361-71
pubmed: 25741681
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Tob Control. 2017 Mar;26(e1):e3-e4
pubmed: 27821791
JAMA Netw Open. 2019 Feb 1;2(2):e187794
pubmed: 30707232
Tumori. 2020 Apr 26;:300891620915784
pubmed: 32338200
Tob Control. 2016 Mar;25(2):174-80
pubmed: 25361744
Prev Med. 2020 Feb 3;133:106009
pubmed: 32027913
J Epidemiol. 2021 Jan 16;:
pubmed: 33456019
BMJ. 2013 Jun 14;346:f3840
pubmed: 23771038
Prev Med. 2013 May;56(5):314-8
pubmed: 23462480
J Epidemiol. 2018 May 5;28(5):274-275
pubmed: 29657258
Am J Prev Med. 2015 Aug;49(2):199-206
pubmed: 25840880
Curr Cardiol Rep. 2019 Aug 28;21(10):111
pubmed: 31463564
Tob Control. 2019 Jan;28(1):113-114
pubmed: 29374094
Eur Respir J. 2018 May 30;51(5):
pubmed: 29848575
Tob Control. 2016 Nov;25(Suppl 2):ii62-ii66
pubmed: 27633762
Pediatrics. 2015 Nov;136(5):1018-26
pubmed: 26504128
J Epidemiol Community Health. 2009 Jul;63(7):559-62
pubmed: 19289387
Nicotine Tob Res. 2014 Dec;16(12):1541-8
pubmed: 25082832
Ann Oncol. 2006 Feb;17(2):346-7
pubmed: 16275652
Tumori. 2017 Jul 31;103(4):353-359
pubmed: 28574129
Tob Control. 2020 Mar;29(2):148-152
pubmed: 30659103
Am J Prev Med. 2017 Aug;53(2):139-151
pubmed: 28318902
Pediatrics. 2018 Apr;141(4):
pubmed: 29507167
Int J Drug Policy. 2020 Sep 16;86:102941
pubmed: 32949900
J Epidemiol. 2020 Dec 19;:
pubmed: 33342937
Tob Control. 2020 Jul;29(4):381-387
pubmed: 31209129
Addict Behav Rep. 2020 Jan 20;11:100246
pubmed: 32467835

Auteurs

Silvano Gallus (S)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.

Elisa Borroni (E)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.

Anna Odone (A)

Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
School of Medicine, University Vita-Salute San Raffaele, 20132 Milan, Italy.

Piet A van den Brandt (PA)

Department of Epidemiology, CAPHRI-School for Public Health and Primary Care, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.
Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.

Giuseppe Gorini (G)

Oncologic Network, Prevention and Research Institute (ISPRO), 50139 Florence, Italy.

Lorenzo Spizzichino (L)

Italian Ministry of Health, Center for Disease Prevention and Control, 00144 Rome, Italy.

Roberta Pacifici (R)

National Centre on Addiction and Doping, Istituto Superiore di Sanità, 00161 Rome, Italy.

Alessandra Lugo (A)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH